Frontiers in pharmacology
Cure8 research brief
Why This Matters
Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists in trial data, which could influence treatment discussions when EIMs are a major concern.
Who Should Pay Attention
Adults with Crohn's disease (especially those with bothersome fatigue or joint symptoms), clinicians treating IBD, researchers studying biologic treatments and EIMs, and patients considering or on biologic therapy.
Study Snapshot
Story typeResearch paper
Evidence typeSystematic review
Source depthJournal abstract
What To Know
This paper reviewed phase II and III randomized controlled trials in adults with moderate-to-severe Crohn's disease and focused on EIMs like fatigue, joint pain, and skin manifestations. The authors report statistically significant reductions in fatigue (overall) and arthritis/arthralgia during maintenance for ustekinumab.
By contrast, weekly adalimumab was associated with increased risk of fatigue in one pooled analysis, and infliximab and adalimumab did not show consistent benefits across most EIM endpoints. The study pooled data from 23 RCTs with 7,810 patients and used standard meta-analytic techniques and PRISMA guidance.
The results summarize trial-reported EIM outcomes rather than dedicated EIM-targeted trials; individual patient factors and trial designs varied across studies.
Keep In Mind
The meta-analysis synthesizes RCT data where EIMs were often trial-reported outcomes rather than primary endpoints; reporting and definitions varied. The source is an abstract/structured —interpretation should consider individual study differences and seek the full text for detailed methods and subgroup analyses.
Source Details
Review the original publication for the complete reporting, methods, and context.
Systematic review
Evidence type derived from source or registry metadata.
PublicationFrontiers in pharmacology
AuthorsLin MX, Chen YX, Ding TN +9 more
Study typeSystematic review, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 30, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.